Key result
In patients with cardiogenic shock, 30-day mortality with Impella support was 47.8%, with improved survival associated with Impella 5.0 or CP use and initiation prior to revascularization.
Why the study?
The clinical impact of invasive hemodynamic support with Impella in patients with cardiogenic shock remained to be defined.
Does Impella improve short term mortality in patients with cardiogenic shock?
Population
3933 patients with cardiogenic shock across 17 studies
Comparison
Impella invasive hemodynamic support
Design
Review and meta-analysis of observational studies
Follow-up
30-day
Authors
Loading...
Mortality exceeds 45% with Impella in CS; leaves open whether device type or pre-PCI timing improves outcomes in prospective trials.
Meta-Analysis (n=3,933)
Does Impella improve short term mortality in patients with cardiogenic shock?
In patients with cardiogenic shock, 30-day mortality remains high at 47.8% despite Impella use, though Impella CP/5.0 and early initiation prior to PCI or cardiac arrest may be associated with improved survival.
Iannaccone et al. (2020) conducted a meta-analysis in Cardiogenic shock (n=3,933). Impella was evaluated on Short term mortality. In patients with cardiogenic shock, 30-day mortality with Impella support was 47.8%, with improved survival associated with Impella 5.0 or CP use and initiation prior to revascularization.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: